Background: Alcohol use disorders (AUD) are highly disabling. Recent studies reported much higher relative risks for all-cause mortality in AUD patients compared with earlier studies. Systematic evidence regarding cause-specific mortality among AUD patients has been unavailable to date. Methods: Studies were identified through MEDLINE, EMBASE and Web of Science up to August 2012. Following MOOSE guidelines, prospective and historical cohort studies assessing cause-specific mortality risk from AUD patients at baseline compared with the general population were selected. Data on several study characteristics, including AUD assessment, follow-up period, setting, location and cause-specific mortality risk compared with the general population were abstracted. Random-effect meta-analyses were conducted. Results: Overall, 17 observational studies with 6420 observed deaths among 28 087 AUD patients were included. Pooled standardized mortality ratios (SMRs) after 10 years of follow-up among men were 14.8 (95% confidence interval: 8.7-24.9) for liver cirrhosis, 18.0 (11.2-30.3) for mental disorders, 6.6 (5.0-8.8) for death by injury and around 2 for cancer and cardiovascular diseases. SMRs were substantially higher in women, with fewer studies available. For many outcomes the risk has been increasing substantially over time. Conclusions: Cause-specific mortality among AUD patients was high in all major categories compared with the general population. There has been a lack of recent research, and future studies should focus on the influence of comorbidities on excess mortality risk among AUD patients. Efforts to reduce these risks should be a priority, given that successful treatment reduces mortality risk substantially for a relatively common psychiatric disease.
Introduction
Alcohol use disorders (AUD), comprising alcohol dependence and alcohol abuse, are one of the most prevalent mental disorders, affecting an estimated 3.6% of the population between 15 and 64 years of age worldwide (men ¼ 6.3%; women ¼ 0.9%). 1 The overwhelming majority of people with AUD, whether identified by Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria, do not receive treatment, with less than 10% treated in Europe or the USA (for the US: Hasin et al.
(DSM-IV); for
Europe: Rehm et al. 3 (DSM or ICD) and Alonso et al.
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(DSM-IV); for an overview: 5 ; in fact the treatment gap for AUD is larger than for any other mental disorder. 5 Like most other mental disorders, AUD have been considered to be more disabling than fatal, [6] [7] [8] and a metaanalysis from 1998 in part supported this view, 9 with relatively low estimated all-cause standardized mortality ratios (SMRs) for AUD of 1.80 [95% confidence interval (CI): 1.76-1.84] for men and 3.84 (95% CI: 3.54-4.15) for women. However, the underlying analyses included several definitions of heavy alcohol use and the samples were taken from various clinical and non-clinical contexts, including from drunk driver databases, Veteran Affairs databases and general population surveys. There is evidence that different sampling is associated with differing mortality risks, with clinical samples of AUD showing higher levels of mortality compared with general population surveys. 10, 11 Moreover, more recent publications indicated a higher level of AUD-related mortality risks for clinical populations compared with earlier publications. [12] [13] [14] [15] This led to a reexamination of mortality associated with AUD via systematic review and meta-analyses, which indeed found a higher relative risk than previously assumed, specifically for AUD patients. 16 This article tries to go one step further and examines the underlying causes of death in AUD treatment patients. The cause-specific mortality risk among participants in treatment for AUD, i.e. for the most severe cases of AUD, 17 has not been systematically examined to our knowledge. However, cause-specific mortality is important, as it has clinical implications for treatment of AUD such as the decision to include systematic screening for other diseases.
Materials and Methods

Search strategy
This meta-analysis followed the MOOSE guidelines. 18 The following electronic databases were searched from their inception to the first week of August 2012 for original articles, excluding letters, editorials, conference abstracts, reviews and comments: MEDLINE and EMBASE (through OVID) and Web of Science (Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index). Search terms included: (alcohol dependence OR alcohol abuse) AND (mortality) AND (cohort OR follow-up). Additionally, reference lists of identified articles were searched.
of relative risk (SMR, hazard ratio, relative risk, odds ratio) compared with the general population, and its variance or enough data to calculate these; (v) were at least age-standardized or -adjusted and sex-stratified; (vi) were of English-, German-or Spanish-language. Articles were initially screened for inclusion by title and abstract, followed by full-text review.
Data extraction
From all relevant articles we extracted authors' names, year of publication, country, year(s) of baseline examination, follow-up duration (years), setting, assessment of AUD diagnosis, mean age at baseline, sex, number of observed deaths among AUD patients, number of total patients with AUD included, adjustment for potential confounders, and relative risk (RR) and its standard error. Causes of death abstracted were: cardiovascular diseases (CVD, sub-categories were heart diseases and cerebrovascular diseases), cancers, injuries (sub-categories were unintentional injuries and suicide), digestive diseases (subcategory was liver cirrhosis), mental diseases, respiratory diseases (sub-category was pneumonia) and endocrine diseases (sub-category was diabetes). In case only liver cirrhosis, heart disease, pneumonia or diabetes were reported in primary studies, we also used these estimates in overall categories such as digestive disease, CVD, respiratory diseases or endocrine diseases. This decision was made because the vast majority of deaths were observed in those subcategories. The above described categorization was derived from death categories known to be associated with heavy drinking or AUD. 9, 19, 20 Several versions of the International Classification of Diseases (ICD) were used in primary studies, but all studies were based on death certificates, oftentimes using additional sources of information about the cause of death.
Quality assessment
Most quality scores are tailored for meta-analyses of randomized trials of interventions (e.g. see Moher et al.
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) and many criteria do not apply to descriptive longitudinal studies like the ones examined here. Also, the use of quality scores in meta-analyses remains controversial. 22, 23 Thus, we decided to incorporate quality assessment differently by including quality components such as study design into the inclusion and exclusion criteria. In addition, we used potential quality criteria as independent variables in metaregressions. One author performed the literature search and abstracted the data. To control for subjectivity, 10 papers were randomly selected and extracted by the second author. No changes in abstraction were recorded. Authors from primary studies were not contacted in case insufficient information was provided.
Statistical analysis
SMRs (i.e. comparisons of mortality risks of people with AUD with the age-and sex-specific general population; see 24 ), hazard ratios, odds ratios and relative risks were treated as equivalent measures of risk. All analyses were stratified by sex. We excluded estimates when both exposure and control group reported one or less deaths in both groups. When sub-categories within our classification of cause of death categories were the only ones reported, we combined those by summing up observed and expected death from each sub-category, or by combining the reported RRs using fixed-effect modelling to derive one effect estimate per category per study for each analysis. SMRs were pooled across studies using inverse-variance weighted DerSimonian-Laird random-effect models to allow for between-study heterogeneity. 25 We quantified between-study heterogeneity using Cochran's Q 26 and the I 2 statistic. 27 I 2 can be interpreted as the proportion of the total variation in the estimated effects for each study that is due to heterogeneity between studies. Meta-regression was conducted to identify study characteristics that influenced the association between AUD in treatment and causespecific mortality. Potential publication bias was examined using Egger's regression-based test. 28 These tests were only conducted when there were 10 or more studies available.
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Sensitivity analyses for the influence of single studies on the pooled SMRs were conducted omitting studies one by one and re-estimating the pooled SMRs. All meta-analytical analyses were conducted on the natural log scale in Stata statistical software, version 11.1 (Stata Corp, College Station, TX).
Results
Literature search
The literature search identified 2063 references ( Figure 1 , available as Supplementary data at IJE online). After removal of duplicates, 1805 unique references were screened for inclusion. Of those, after exclusion based on title and abstract, 193 papers were obtained in full text. In total, 17 unique articles meeting the inclusion criteria were used in this meta-analysis (Table 1) . Overall, six studies were conducted in Sweden, three each in the USA and Japan and one each in Norway, Canada, the UK, Italy and Iceland. In total, 6420 deaths were observed among the AUD patient group, with 28 087 people with AUD at risk. Follow-up time ranged from 2.8 to 30 years with a weighted average of 11.5 and 10.5 years among men and women, respectively. All but one study reported SMRs.
Alcohol use disorder in treatment and cause-specific mortality
Pooled SMRs for cause-specific mortality are displayed in Table 2 for men and Table 3 and digestive diseases (12%, range 2-29). In women, trauma was most prevalent (29%, range 11-71), followed by CVD (21%, range [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , digestive diseases (19%, range 8-33) and cancer (18%, range 6-26). Subcategories of CVD, such as heart disease and cerebrovascular diseases as well as diabetes showed similarly elevated mortality risks compared with more general categories. Similar results were seen in women; however, injuries, liver cirrhosis and mental disorders showed 20-to 30-fold mortality risks compared with the general population. The number of women in primary studies was generally lower than the number of men, reflecting gender difference in prevalence of AUD (see above).
Meta-regression and sensitivity analyses
None of the studies in the analyses had a strong influence on the pooled results. All pooled estimates were well within the confidence intervals when omitting studies one by one and calculating the pooled SMR for the remaining studies. Between-study heterogeneity was generally high in all analyses as indicated by I 2 (see Tables 2 and 3) . Because of the low number of studies available for women, regression-based tests were only conducted among men. Only one of nine disease outcomes showed some evidence for publication bias ( Cumulative meta-analyses based on mean (calendar) year of baseline assessment showed that CVD (Figure 1) , digestive disease ( Figure 2 ) and endocrine disease (Figure 3 ) mortality risk increased about 2-to 3-fold over time in men. These changes were quite similar for sub-categories of CVD and digestive diseases. Fewer studies were available in women, and such changes were generally not evident, except for a slight increase in cancer mortality ( Figure 4 ).
Discussion
Our meta-analysis of relative mortality risk in people with AUD in treatment showed high cause-specific pooled SMRs across the board, in line with a recent meta-analysis on all-cause mortality. 16 The mortality risk for many causes of death categories was increasing over time.
However, there was a striking lack of recent evidence as only two studies with a baseline assessment after 1990 were identified. Clearly, given the effect sizes found, there is a dire need for more detailed studies on cause-specific mortality in AUD patients, in particular given the increase in mortality risk over time seen for CVD, digestive and endocrine diseases in men, and cancer mortality in women in the cumulative meta-analyses.
Limitations
Some limitations (both general and specific) apply to our meta-analysis. First, the analysis was limited to English-, German-and Spanish-language studies, leaving the possibility of unidentified studies. Second, there was large between-study heterogeneity detected in all analyses. This heterogeneity would be more important if the effects were small; however, all pooled SMRs were large. Nevertheless, we expect that there was at least some clinically important heterogeneity within our sample of studies, and later studies focused on alcohol dependence or detoxification indicating increased case severity. Differences in case severity (including comorbidities), results or type of treatment received, or uncontrolled confounding all may have contributed to any observed between-study heterogeneity. Whereas our study did not differentiate between AUD treatment outcomes, it seems likely that the SMRs for mortality in people with AUD who relapse or continue to drink heavily are even higher than we report in this metaanalysis, given the reduced mortality risk for people with AUD who reduce their consumption or become abstinent (see below and Hasin et al., 2 Rehm et al., 30 and Roerecke et al.
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). Which causes of deaths are avoided by successful AUD treatment and by which degree might be differential by category of cause of death, as different causes have differential pathways. Again, exploring the pathways from AUD to death should be a priority for future research, as our knowledge in this area seems only rudimentary. In addition, since average drinking at baseline in alcohol treatment varies considerably between studies and countries, the same formal inclusion criterion of AUD in treatment can be linked to a variety of different underlying exposures in terms of level and patterns of drinking as well as severity of AUD. 32 Only one study 33 reported risk estimates adjusted for more than just age; one other study also adjusted for length of follow-up. Thus, confounding from factors other than age and sex could not be examined in our study. Furthermore, the lack of recent studies is problematic because characteristics of AUD may have changed over time with regard to treatment availability or uptake, comorbidities or age distribution. Because our metaanalysis included a comparison of AUD patients in treatment with the general population, we cannot comment on the cause-specific mortality risks of AUD identified in population surveys. Although the risks are expected to be slightly lower when based on lower all-cause mortality risk, 16 the most severe cases of AUD are typically missed in population surveys 34 such as people in treatment, 35, 36 and in marginalized populations, i.e. the homeless 37 and prisoners. 38 
Causes of death
In the following, we will discuss cause-specific outcomes. Given the often emphasised beneficial effect of alcohol consumption on CVD, in particular heart disease outcomes and possibly diabetes, it has to be noted that none of the causes of death in people with AUD in treatment examined here showed any beneficial association. Although there is good epidemiological and short-term experimental evidence for a beneficial effect on ischaemic disease and possibly diabetes from regular low-level alcohol consumption, 20,39-42 based on our meta-analysis there is a substantially elevated risk for diabetes, all CVD in general and heart disease in particular in the highest alcohol consumption group as measured by current AUD treatment at baseline. This corroborates the findings of Russian studies, where high SMRs had been found for CVD including heart disease linked to very heavy drinking (e.g. Zaridze et al.
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). One open question is whether prolonged binges pose additional problems compared with chronic heavy drinking, if the overall exposure is the same. 43 The risk for several cancers is positively correlated with level of alcohol consumption. Recently, the list of cancers causally affected by alcohol consumption was expanded to now include oral cavity, pharynx, larynx, oesophagus, liver, colorectal and female breast cancer. 44, 45 There is a clear dose-response relationship for all cancers described, and a relatively long latency.
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The effects of alcohol on several gastrointestinal disease categories are evident by several ICD categories having 'alcohol' or 'alcoholic' in their name, such as alcoholic gastritis, alcoholic liver disease or alcohol-induced pancreatitis. 46 The negative effects of alcohol consumption on these diseases grow exponentially with higher alcohol consumption. 47, 48 This would explain the relatively high SMRs for gastrointestinal diseases compared with cancer.
Another category for cause of death with high risk for people with AUD was mental disorders. In earlier studies, this category included mostly 'alcoholism'. Although the absolute number of deaths in this category was relatively small, the SMRs were substantial. The comorbidity between AUD and other mental disorders is quite high, 49,50 but causality is not clear, as AUD could be caused by mental disorders, mental disorders could be caused by AUD, or a third factor such as genetic vulnerability could cause both.
Our estimates for suicide were twice as high among men, and similar among women compared with the last review. 51 One reason might be that Wilcox et al. included not only treatment samples but also population samples. Comorbidity among AUD patients who commit suicide seems to be high, in particular depression 52 (see also above). A recent cohort study showed that among AUD patients without other psychiatric disorders the risk was similar to our findings; however, when other psychiatric disorders were present, adjusted risk estimates associated with AUD were much lower, about half the suicide risk compared with unadjusted estimates. 53 A causal effect from alcohol on injuries has long been established, with a causal mechanism being mainly heavy drinking episodes and the resulting high blood alcohol level 54 which is very characteristic of people with AUD. 49, 55 Heavy drinking has been identified as a major cause for respiratory disease, 56 explaining the higher risk of these causes of death for people with AUD. The causal pathway is mainly via a compromised immune system, 57 and the risks for pneumonia have been mainly established for heavy drinking above a certain threshold. 58 
Implications
People with AUD who seek treatment were associated with high mortality risk in all major causes of death categories. A lack of systematic investigations on why some mortality risks were increasing over time among AUD patients warrants further research. The high mortality risks shown in this analysis should not be interpreted that treatment for AUD does not work. On the contrary, several studies (e.g. [59] [60] [61] [62] ) showed that a reduction of drinking substantially reduced total mortality risk (see also Rehm et al. 30 ). The risk of injury death is extremely high, in particular in women, and targeted prevention should be considered for those seeking treatment. Health-care contacts, such as AUD treatment, open a window of opportunity for intervention, trying to reduce this high mortality from disease and injury. Treatment for AUD should include screening for these common diseases among people with AUD (such as liver cirrhosis or common CVD-see European Association for the Study of the Liver 63 for liver cirrhosis, or http://guideline.gov/content.aspx?id¼34783 for CVD). Given the high mortality risk for all major disease categories, screening for AUD should be more routinely incorporated into medical practice for somatic diseases in primary and secondary healthcare settings. This may help to identify people with alcohol problems and AUD earlier and reduce the development of more severe forms of addiction, while simultaneously reducing detrimental effects of alcohol consumption on the underlying conditions. This could be done via the General Practice system with proven effective screening and brief interventions. 64 This setting also seems to be important because many people with AUD have general practitioner contact. 65 However, it will be necessary to implement an incentive system to guarantee uptake of such techniques in daily practice. 66 The potential impact of brief interventions on mortality can also be seen in hospital settings. The last Cochrane review found a reduction of 40% of mortality within 1 year after brief interventions in such settings in randomized controlled trials, mainly conducted in internal and injury wards. 67 This shows the potential of even minimal interventions in settings with high risk, where reduction of drinking level is crucial for survival. 30 However, brief interventions may need to include not only one but several sessions to be most effective. 68 Of course, reduction of mortality risk is not restricted to brief interventions, but is associated with all interventions which successfully reduce volume of drinking including, but not limited to, formal treatment. Based on effectiveness of current interventions for AUD, it was estimated that almost 12 000 alcohol-attributable deaths in the EU could be saved within 1 year if treatment rates were to be increased to 40%. 3 The high rates of mortality shown here thus could markedly be reduced if more interventions for problem drinking and AUD were implemented.
Conclusion
Cause-specific mortality among people with AUD in treatment showed markedly higher and increasing mortality risks compared with the general population than previously thought in most major categories, including CVD.
Efforts to reduce these risks should be a priority, given that successful treatment reduces mortality risk substantially for a relatively common disease. There is a lack of recent research and future studies should focus on potential influence of age differences and comorbidities on excess mortality risk in people with AUD.
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